Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05651204 · ClinicalTrials.gov registry record
GABA Biomarkers in Dravet Syndrome
A clinical trial of Dravet Syndrome, sponsored by Cook Children's Health Care System.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT05651204 is a study of Dravet Syndrome that is actively recruiting participants, run by Cook Children's Health Care System. The registered enrollment target is 36 participants, below the 107-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05651204, a study of Dravet Syndrome, is actively recruiting participants, sponsored by Cook Children's Health Care System.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST GABA Blood Level
Study Locations (1)
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2027-09-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05651204
The ClinicalTrials.gov registry entry for NCT05651204 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 12 other Dravet Syndrome trials with a reported enrollment target (66% lower). The listed sponsor is Cook Children's Health Care System, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dravet Syndrome appearing as the primary indexed condition, and to 1 intervention - of which GABA Blood Level is the first listed.
NCT05651204 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05651204 about?
NCT05651204 is a clinical study titled "GABA Biomarkers in Dravet Syndrome". This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.
What is the current status of trial NCT05651204?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2022-09-08. Estimated completion is 2027-09-08.
What conditions does trial NCT05651204 study?
This clinical trial studies the following conditions: Dravet Syndrome.
What interventions are being tested in trial NCT05651204?
The interventions under investigation include: GABA Blood Level (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05651204?
This trial is sponsored by Cook Children's Health Care System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05651204 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dravet Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RECRUITING · Phase 1
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RECRUITING · Phase 3
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
RECRUITING · Phase 3
-
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
ACTIVE NOT RECRUITING · Phase 4
-
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.